dav1234,
I don't have a precise number on CLDX, because I don't know how to value CDX-1135 and CDX-1127, which are both reporting some data this year and are, I believe, significant value drivers for CLDX in addition to 001 and 011. The latter two have been driving the price. CLDX will also be report some early data on 1401 and 301 in the next couple of months. All of these molecules are proprietary. I am hoping that CLDX partners both 001 and 011, especially the latter, which needs to be tested in a variety of cancer indications. CLDX just doesn't have the resources, IMO, to do this kind of development.
The fact that Wedbush believes that Rindopepimut can be a billion dollar drug comes as a surprise to me.
Bladerunner
Market Data 
Markets 
AI
